PRN: The Global Mobile Messaging Market Will be Worth 305.5 Billion Dollars by 2016 Says Latest Visiongain Report

14/dic/2011 12.01.00 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

The Global Mobile Messaging Market Will be Worth 305.5 Billion Dollars by 2016 Says Latest Visiongain Report

 
[14-December-2011]
 

LONDON, December 14, 2011 /PRNewswire/ --

http://www.visiongain.com/Report/735/Mobile-Messaging-Market-Report-2011-2016

Visiongain's latest research entitled "Mobile Messaging Market Report: 2011 - 2016" offers a fine-tuned analysis of four mobile messaging platforms: SMS, MMS, instant messaging and email.

The mobile messaging market is under strong pressure to evolve and adapt alongside technical innovation and changes in consumer demands. The strong growth of mobile broadband is the result of increased mobile data usage by subscribers hungry for instant communication, multimedia sharing and social networking. Instant messaging and email applications are fast becoming default services in smart devices.

Smartphones and mobile broadband are not the only vectors for the transformation of the mobile messaging market. SMS and MMS have also evolved beyond their traditional platforms to more enhanced and personalised applications. Ubiquitous wireless connectivity and basic feature phones have become quasi-universal on a global scale. In many regions, basic mobile messaging is serving as an efficient and reliable platform for value added services in mobile banking, commerce and health.

The mobile messaging market is undergoing a structural shift and opening up to new players offering high-value functionalities. Visiongain estimates the current market to be valued at US $202 billion which represents on average 19% of total global mobile revenues. While North America and Europe will show a strong uptake and diversification in instant messaging and email services, emerging economies in Africa, the Middle East and Asia will see continued growth and expansion of traditional SMS and MMS platforms and their use in new industries.

Visiongain's report presents a detailed breakdown of the four mobile messaging ecosystems, including market dynamics, the role of different industry stakeholders and the financial forecasts for revenue and subscriptions evolution at the global and regional level. The research analyses the emerging trends and opportunities for operators, content and service providers, manufacturers, commercial organisations as well as government institutions to harness the potential offered by messaging platforms in an increasingly mobile world.

To view sample pages please click on:

http://www.visiongain.com/Report/735/Mobile-Messaging-Market-Report-2011-2016

1. Executive Summary
1.1 Summary Points of this Report
1.2 Aims, Scope and Format of the Report
1.2.1 Speculative Aspects of Assessing the Biobanking Market
1.2.2 Chapter Outlines
1.3 Research and Analysis Methods
1.3.1 Human Tissue Banking Market
1.3.2 Stem Cell Banking Market

2. Introduction to Biobanking
2.1 Biobanking
2.1.1 Processes Involved in Biobanking
2.2 Biobanks: A Two-Fold Character
2.3 Key Features
2.4 Classification of Biobanks
2.4.1 Volunteer Groups
2.4.1.1 Population-Based Biobanks
2.4.1.2 Disease-Oriented Biobanks
2.4.2 Ownership or Funding Structure
2.5 Guidelines and Standards
2.5.1 Guidelines for Biobanks and Use of Biological Samples for Research
2.5.2 Industry Standards for Biobanks
2.5.3 Biobanking Processes Governed by Guidelines
2.6 Laws and Regulations for Biobank-Based Research

3. Biobanking and the Pharmaceutical Industry
3.1 Scientific and Commercial Use of Biobanking in the Pharmaceutical Industry
3.1.1 Research and Drug Development
3.1.1.1 Understanding Disease Pathways
3.1.1.2 Drug Discovery
3.1.1.3 Biomarker Discovery
3.1.2 Therapeutics
3.1.3 Clinical Trials
3.2 Biobanks Operated by Pharmaceutical Companies

4. Biobanking Associated Market: Systems, Software, Consumables and Services Associated with Biobanking
4.1 Overview
4.2 Systems/Technologies
4.2.1 Automated Liquid Handling
4.2.1.1 Frozen Aliquotting: New Technology in Development
4.2.2 Storage
4.2.2.1 Ultra-Low Temperature Freezing
4.2.2.2 Room-Temperature Storage
4.2.3 RFID and Tagging Technologies
4.3 Software
4.3.1 Laboratory Information Management System (LIMS)
4.3.1.1 LIMS Functions
4.4 Consumables
4.5 Services

5. The World Medical Biobanking Market to 2022
5.1 Current State of the Biobanking Market
5.2 Geographical Footprint
5.3 Growing Demand for Biobank Resources
5.4 Revenue Forecast for Overall Market
5.4.1 Scope and Limitations
5.4.2 Biobanking Market, 2011-2022
5.4.2.1 Sales Forecasts for Biobanking Market, 2011-2016
5.4.2.2 Sales Forecasts for Biobanking Market, 2017-2022
5.5 Commercial Biobanks: New Resources for Research

6. Human Tissue Banking Market
6.1 Revenue Forecast for Overall Human Tissue Banking Market, 2011-2022
6.1.1 Revenue Forecast for Overall Human Tissue Banking Market, 2011-2016
6.1.2 Revenue Forecast for Overall Human Tissue Banking Market, 2017-2022
6.2 Revenue Forecasts for Human Tissue Banking Market by Type of Biobank, 2011-2022
6.2.1 Revenue Forecast for Commercial Human Tissue Banking Market, 2011-2016
6.2.2 Revenue Forecast for Commercial Human Tissue Banking Market, 2017-2022
6.2.3 Revenue Forecast for Academic & Other Human Tissue Banking Market, 2011-2016
6.2.4 Revenue Forecast for Academic & Other Human Tissue Banking Market, 2017-2022
6.3 Revenue Forecasts for Human Tissue Banking in Leading National Markets, 2011-2022
6.4 Some Commercial Participants in the Human Tissue Banking Market
6.4.1 Business Models of Companies in the Biobanking Market
6.4.2 Tissue Solutions
6.4.2.1 Overview
6.4.2.2 Global Presence
6.4.2.3 Products and Services
6.4.2.3.1 Banked Samples
6.4.2.3.2 Prospective Samples
6.4.2.3.3 Fresh Samples
6.4.2.3.4 Freshly Isolated and Primary Cells
6.4.2.3.5 Services
6.4.2.4 Strengths and Capabilities
6.4.2.5 Future Outlook
6.4.3 Asterand
6.4.3.1 Overview
6.4.3.2 Global Presence
6.4.3.3 Products and Services
6.4.3.3.1 XpressBANK
6.4.3.3.2 ProCURE
6.4.3.3.3 PhaseZERO
6.4.3.3.4 BioMAP
6.4.3.4 Asterand: Raised Barriers for New Market Entrants?
6.4.3.5 Financial Performance
6.4.3.6 Future Outlook

7. Stem Cell Banking
7.1 Overview
7.2 Revenue Forecast for Overall Stem Cell Banking Market, 2011-2022
7.2.1 Revenue Forecast for Stem Cell Banking Market, 2011-2016
7.2.2 Revenue Forecast for Stem Cell Banking Market, 2017-2022
7.3 Stem Cell Banks for Research: High Growth Possible
7.4 Umbilical Cord Blood Banking for Stem Cells
7.4.1 Blood Banks: Private vs. Public
7.4.2 Biological Insurance: Private Blood Banking
7.4.3 Umbilical Cord Banking: The Controversies
7.4.3.1 US Oversight of Cord Blood Stem Cells
7.4.4 Revenue Forecast for Private Cord Blood Banking Market, 2011-2016
7.4.5 Revenue Forecast for Private Cord Blood Banking Market, 2017-2022
7.4.6 Companies in the Field
7.4.6.1 Cord Blood America: Looking Towards the Chinese Market
7.4.6.2 ViaCord: 145,000 Blood Units in Storage
7.4.6.3 Cryo-Cell International: The First Cord Blood Bank
7.4.6.4 Stem Cell Authority: Exclusive Stem Cells
7.4.6.5 LifebankUSA: Placenta-Cord Banking
7.4.6.6 Biogenea-Cellgenea
7.4.6.7 China Cord Blood Corp
7.4.6.8 Cryo-Save
7.4.6.9 Thermogenesis
7.5 Gene/DNA Banking

8. Industry Trends
8.1 Automated Biobanking
8.1.1 Increased Uptake of Laboratory Information Management Systems (LIMS) in Biobanking
8.1.2 Addressing Sample Storage and Tracking Issues
8.2 Green Banking
8.3 Creation of National Biobanks
8.4 HIPAA Amendments

9. Qualitative Analysis of the Biobanking Sector
9.1 Strengths
9.1.1 Wealth of Information for Genetic Research
9.1.2 Potential to Change Treatments
9.1.3 Many Governments Support Biobanking
9.2 Weaknesses
9.2.1 Quality Concerns for Some Existing Biospecimen Collections
9.2.2 Lack of Standardisation and Harmonisation of Best Practices
9.2.3 Limited Sharing and Linkage of Biobanks
9.3 Opportunities
9.3.1 Genome-Wide Association Studies (GWAS)
9.3.2 Personalised Medicine
9.3.3 Pharmacogenomics: Driving the Personalised Medicine Approach
9.4 Threats
9.4.1 Ethical and Regulatory Issues
9.4.1.1 Limitations of Informed Consent in Biobanking
9.4.1.2 Confidentiality and Security to Prevent Improper Use
9.4.2 Social and Cultural Issues
9.4.3 Ownership Issues
9.4.4 Funding

10. Research Interviews from Our Survey
10.1 Dr Morag McFarlane, Chief Scientific Officer, Tissue Solutions
10.1.1 On the Use of Biobank Samples in the Pharmaceutical Industry 
10.1.2 On Commercial Aspects of Biobanking
10.1.3 On the Business of Tissue Solutions
10.1.4 On the Attractiveness of Human Tissue Banking
10.1.5 On the Future of the Biobanking Market
10.2 Dr Angel García Martín, Director, Inbiomed
10.2.1 On the Importance of Biobanking in the Pharmaceutical Industry 
10.2.2 On the Use of Technology in Biobanking 
10.2.3 On Increased Recognition of Biobanking and Harmonisation of Samples 
10.2.4 On the Use of Biobanks by the Pharmaceutical Industry 
10.2.5 On Private Biobanks and Scale of Operations 
10.2.6 On Commercial and Public Biobanking and Legislation 
10.2.7 On the Most Attractive Segment in Commercial Biobanking
10.2.8 On the Future of Biobanking: Drivers and Challenges
10.3 Dr Piet Smet, Director, Business Development, BioStorage Technologies
10.3.1 On Defining Biorepositories and Biobanks
10.3.2 On the Services of Biostorage
10.3.3 On Main Customers for Biostorage
10.3.4 On the Importance of Biorepositories in Research and Industry
10.3.5 On Technology Use in Biobanks
10.3.6 On Increased Recognition of Biobanking and Harmonisation of Samples 
10.3.7 On the Use of Biobanks by the Pharmaceutical Industry 
10.3.8 On Private Biobanks and Scale of Operations 
10.3.9 On Commercial and Public Biobanking and Legislation 
10.3.10 On the Most Attractive Segment in Commercial Biobanking
10.3.11 On Biobanking in 2020
10.3.12 On Drivers and Challenges in the Sector
10.4 Dr Tom Hoksbergen, Marketing and Sales, SampleNavigator Laboratory Automation Systems
10.4.1 On the Services of SampleNavigator
10.4.2 On Main Customers for SampleNavigator
10.4.3 On the Importance of Biorepositories in Research and Industry
10.4.4 On Technology Use in Biobanks
10.4.5 On Increased Recognition of Biobanking and Harmonisation of Samples 
10.4.6 On the Use of Biobanks by the Pharmaceutical Industry 
10.4.7 On Commercial Biorepositories/Banks and Scale of Operations 
10.4.8 On Commercial and Public Biobanking
10.4.9 On the Most Attractive Segment in Commercial Biobanking
10.4.10 On Biobanking in 2020
10.4.11 On Drivers and Challenges in the Sector
10.5 Mr Rob Fannon, Clinical Operations Manager, BioServe
10.5.1 On the Services of BioServe
10.5.2 On Main Customers for BioServe
10.5.3 On the Importance of Biorepositories in Research and Industry
10.5.4 On Technology Use in Biobanks
10.5.5 On Increased Recognition of Biobanking and Harmonisation of Samples 
10.5.6 On the Use of Biobanks by the Pharmaceutical Industry 
10.5.7 On Commercial Biorepositories/Banks and Scale of Operations 
10.5.8 On Commercial and Public Biobanking
10.5.9 On the Most Attractive Segment in Commercial Biobanking
10.5.10 On Biobanking in 2020
10.5.11 On Drivers and Challenges in the Sector
10.6 Dr Frans A.L. van der Horst, Chairman, Dutch Collaborative Biobank
10.6.1 On Importance of Biorepositories in Research and Industry
10.6.2 On Increased Recognition of Biobanking and Harmonisation of Samples 
10.6.3 On the Services of Dutch Collaborative Biobank
10.6.4 On Commercial Drivers for Bio-Repositories/Biobanking Market
10.6.5 On Commercial and Public Biobanking
10.6.6 On Sustaining/Recovering Costs
10.6.7 On the Most Attractive Segment in Commercial Biobanking
10.6.8 On Ethical, Legal and Social Issues in Biorepositories/Biobanks

11. Conclusions
11.1 Biobanking for Research and Therapeutics
11.2 Biobanking: The Future for Drug Discovery and Personalised Medicine
11.3 Commercial Drivers of the Biobanking Market
11.4 The Sector Has Marked Challenges, but Many Opportunities for Growth

Companies Listed
Abcellute
Abgene
Adnexus Therapeutics
AFNOR Groupe
AKH Biobank
AlloSource
American National Bioethics Advisory Commission 
American Type Culture Collection
Amgen
Analytical Biological Services
ARCH Venture Partners
Asterand
AstraZeneca
Australasian Biospecimen Network (ABN)
Autoscribe
AXM Pharma 
Bayer-Schering
Beckman Coulter
Beike Biotechnology 
Biobank Ireland Trust
Biobank Japan
Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) 
BioFortis
Biogen Idec
Biogenea-CellGenea 
BioLife Solutions
Biomatrica
Biopta
BioRep
BioSeek
BioServe
BioStorage LLC
BioStorage Technologies
BrainNet Europe
Caliper LifeSciences
Canadian Partnership for Tomorrow
CARTaGENE
Cellgene Corporation
Cells4Health
Chemagen
China Cord Blood Corp
Chinese Ministry of Health
CLB/Amsterdam Medical Center
CorCell
Cord Blood America
Cord Blood Registry 
CORD:USE (US Public Cord Blood Bank) 
CordLife
Cordon Vital (CBR) 
Coriell Institute for Medical Research
Council of Europe (CoE)
Covance
Cryo Bio System
Cryo-Cell International
Cryometrix
Cryo-Save
Cureline
Cybrdi
Danubian Biobank Foundation
deCODE Genetics
Department of Health (DoH, UK)
Draper Laboratory
Duke University Medical Center
Dutch Collaborative Biobank
EGeen
Eli Lilly
Eolas Biosciences 
Estonian Genome Project
EuroBioBank
European Commission (EC)
European Health Risk Monitoring (EHRM)
European Medicines Agency (EMA/EMEA)
European Union Group on Ethics (EGE)
Fisher BioServices
Fondazione I.R.C.C.S. Istituto Neurologico C. Besta
Food and Drug Administration (US FDA)
Foundation for the National Institutes of Health 
Fundación Istituto Valenciano de Oncología
Fundeni Clinical Institute
Genentech
Generation Scotland
GeneSaver
GeneSys
Genetic Association Information Network (GAIN)
Genizon Biosciences
Genome Quebec Biobank 
GenomEUtwin
Genomic Studies of Latvian Population
GenVault
German Dementia Competence Network
GlaxoSmithKline (GSK)
H. Lee Moffitt Cancer Center and Research Institute 
Hamilton
Hopital Necker Paris - Necker DNA Bank
Human Tissue Authority (HTA)
Hungarian Biobank
HUNT, Norway
ILSBio LLC
Inbiobank
Inbiomed
Indivumed
INMEGEN
Institut National de la Santé et de la Recherche Médicale (INSERM)
Integrated BioBank of Luxembourg
International Agency for Research on Cancer (IARC)
International Air Transport Association (IATA)
International Organization for Standardization (ISO)
International Society for Biological and Environmental Repositories (ISBER)
International Stem Cell Corporation
Kaiser Permanente
KORA-gen
LabVantage Solutions
LabWare
Leiden University Medical Center
LifebankUSA
LifeGene
LifeStem
Malaysian Cohort Project
Matrical Biosciences
Matrix
Medical Research Council (MRC)
Medical University of Gdansk
Merck & Co.
Merck Sharp & Dohme Limited (MSD)
Merck-Serono
Micronic
Millennium (Takeda Oncology Company)
MVE-Chart
National Cancer Institute (NCI)
National DNA Bank (US)
National Human Genome Research Institute (NHGRI)
National Institute of Environmental Health
National Institutes of Health (NIH)
National Public Health Institute 
National Research Ethics Service (NRES) 
NeoCodex
NeoStem
Neuromuscular Bank of Tissues and DNA Samples
New Brunswick Scientific
NEXUS Biosystems
Northwest Regional Development Agency
Novacare Bio-Logistics
Novartis
NUgene Project
Ocimum Biosolutions
Office of Biorepositories and Biospecimen Research (OBBR)
OnCore UK
Organisation for Economic Co-operation and Development (OECD)
OriGene
Oxagen
Pacific Bio-Material Management
PathServe
Perkin Elmer
Pfizer
Pharmagene Laboratories Trustees Limited
Polaris Ventures 
Pop-Gen (University Hospital Schleswig-Holstein)
PrecisionMed
Prevention Genetics
ProMedDx
Promoting Harmonisation of Epidemiological Biobanks in Europe (PHOEBE)
ProteoGenex
Public Population Projects in Genomics (P3G Consortium)
Qiagen
RAND Corporation
Regenetech
REMP
Reproductive Genetics Institute (RGI)
Research Centre of Vascular Diseases, University of Milan
Rhode Island BioBank, Brown University
Roche
RTS Life Science
Saga Investments LLC
SampleNavigator Laboratory Automation Systems
Sanofi
SANYO Biomedical
Scottish Government
Seattle Genetics
Sejtbank (Hungarian Cord Blood Bank) 
SeqWright DNA Technology Services
SeraCare Life Sciences
Singapore Tissue Network
StarLIMS
Steelgate
Stem Cell Authority
Stem Cells for Safer Medicine (SC4SM)
Stem Cells Research Forum of India
Stemride International
Taiwan Biobank
Taizhou Biobank
TAP
Tecan
The Automation Partnership
The Sorenson Molecular Genealogy Foundation (SMGF)
Thermo Fisher Scientific
Thermogenesis
Tissue Bank Cryo Center (Bulgaria)
Tissue Solutions
Titan Pharmaceuticals
TotipotentSC
Trinity Biobank
Tumorothèque Necker-Entants Malades
UK Biobank
UK Stem Cell Bank
UmanGenomics
Umeå University
University Hospital Angers
University Medical Center Gent
University of Massachusetts Stem Cell Bank
University of Tuebingen, Department of Medical Genetics
US Biomax
Västerbotten County Council
ViaCord
Wellcome Trust
Wellcome Trust Case-Control Consortium (WTCCC)
Western Australian Genome Health Project
Wheaton Science International
Wisconsin International Stem Cell (WISC) Bank
World Health Organization (WHO)
Zhejiang Lukou Biotechnology Co

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.


Please contact Sara Peerun for an exec summary:
Email: sara.peerun@visiongainglobal.com
Tel: +44-020-7336-6100

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl